Features of densitometric assessment of bone tissue parameters in the verification of osteoporotic changes in young men with Hodgkin’s lymphoma

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

BACKGROUND: Factors such as genetic predisposition, lack of sex hormones, low physical activity, and smoking affect the development of osteoporosis in men. Moreover, in young men with Hodgkin’s lymphoma (LH), osteoporosis results from a complex interaction of various factors, including the influence of tumor cells, pathogenetic therapy, and a decrease in androgen concentration, which together leads to a change in bone composition and decrease in bone mineral density (BMD).

AIM: To determine the parameters of BMD in young men with LH and assess the risks of osteoporosis associated with pathogenetic therapy.

MATERIALS AND METHODS: The study included 26 men: 14 were diagnosed with Hodgkin’s lymphoma, and 12 were healthy males (control group). The patients underwent two absorption X-ray scans of bone tissue in the lumbar spine and femur. The following parameters were identified and studied: MPC, Z-criterion, and T-criterion.

RESULTS: BMD analysis showed a significant decrease in this indicator in the upper part of the femur and lumbar spine in patients with LH. Additionally, a decrease in the level of osteopenia or osteoporosis in the lumbar spine was observed in patients with LH. Furthermore, a decrease in the T-criterion level to osteopenia or osteoporosis was noted in the proximal part and neck of the femur in individuals with LH.

CONCLUSION: In young men who have undergone pathogenetic treatment of LH (e.g., cytostatics and glucocorticoids), a significant increase was found in the risk of osteoporosis and related complications. Densitometric examination showed a decrease in BMD and significant changes in the Z-criterion and T-criterion, indicating the development of osteopenia/osteoporosis in the proximal femur and femoral neck. The results demonstrate a high risk of fractures in these areas, which underscores the need for preventive measures.

全文:

受限制的访问

作者简介

Evgeny Praskurnichy

N.I. Pirogov Russian National Research Medical University

Email: praskurnichey@mail.ru
ORCID iD: 0000-0002-9523-5966
SPIN 代码: 5628-1986

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

Amaliya Nagieva

A.I. Burnazyan Federal Medical Biophysical Center

编辑信件的主要联系方式.
Email: nagieva281@gmail.com
ORCID iD: 0009-0006-7653-6620
SPIN 代码: 1521-9584
俄罗斯联邦, Moscow

Yulia Kitaeva

Ural State Medical University

Email: JKhema@yandex.ru
ORCID iD: 0009-0004-5049-1626
SPIN 代码: 2653-9401

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Ekaterinburg

Elena Kuznetsova

Ural State Medical University

Email: aliska@k66.ru
ORCID iD: 0000-0002-1631-486X
SPIN 代码: 1178-7293

MD, Cand. Sci. (Medicine), Associate Professor

俄罗斯联邦, Ekaterinburg

参考

  1. Ministry of Health of the Russian Federation. Clinical recommendations. Osteoporosis. Moscow; 2021. P. 82.
  2. Kaufman JM. Management of osteoporosis in older men. Aging ClinExp Res. 2021;33(6):1439–1452. doi: 10.1007/s40520-021-01845-8
  3. Nikitinskaya OA, Toroptsova NV. Osteoporosis and osteoporotic fractures risk factors in men aged 50 years and older. Osteoporosis and Bone Diseases. 2017;20(1):7–11. EDN: ZWTJMH doi: 10.14341/osteo201717-11
  4. Golovach IYu, Egudina ED. Osteoporosis in men: state of the problem, risk factors, diagnosis, modern approaches to treatment. Travma. 2018;19(5):5–19. EDN: YONXSX doi: 10.22141/1608-1706.5.19.2018.146639
  5. Verbovoy AF, Pashentseva AV, Sharonova LA. Osteoporosis: current state of the art. Terapevticheskii Arkhiv. 2017;89(5):90–97. EDN: YSYUSP doi: 10.17116/terarkh201789590-97
  6. Loures MAR, Zerbini CAF, Danowski JS, et al. Guidelines of the Brazilian Society of Rheumatology for the diagnosis and treatment of osteoporosis in men. Rev Bras Reumatol Engl Ed. 2017;57 Suppl. 2:497-514. doi: 10.1016/j.rbre.2017.07.003
  7. Rinonapoli G, Ruggiero C, Meccariello L, et al. Osteoporosis in men: a review of an underestimated bone condition. Int J Mol Sci. 2021;22(4):2105. doi: 10.3390/ijms22042105
  8. Kitaeva YuS, Praskurnichiy EA. Predictors of bone mineral density reduction in patients with hodgkin’s lymphoma associated with pathogenetic therapy. The Russian Archives of Internal Medicine. 2023;13(1):36–45. EDN: LHFKGU doi: 10.20514/2226-6704-2023-13-1-36-45
  9. Praskurnichy EA, Kitaeva YuS, Kuzneczova EV. Risk factors of osteoporosis and osteopenia associated with pathogenetic therapy of Hodgkin’s lymphoma. Kremlevskaja medicina. Klinicheskij vestnik. 2022;(4):5–8. EDN: CVXMAR doi: 10.48612/cgma/vmet-tkt1-rmgz
  10. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7–16. doi: 10.1007/s12020-018-1588-2
  11. Demina EA, Tumyan GS, Moiseeva TN, et al. Hodgkin’s lymphoma. Journal of Modern Oncology. 2020;22(2):6–33. EDN: MWPSMO doi: 10.26442/18151434.2020.2.200132
  12. Jacobsson M, van Raalte DH, Heijboer AC, et al. Short-term glucocorticoid treatment reduces circulating Sclerostin concentrations in healthy young men: a randomized, placebo-controlled, double-blind study. JBMR Plus. 2020;4(8):e10341. doi: 10.1002/jbm4.10341
  13. Kitaeva YuS, Praskurnichy EA, Konstantinova TS, Kuznetsova EV. Trabecular bone index in assessing the riskof low-energy fractures after courses of polychemotherapy and autologous bone marrow transplantationin patients with Hodgkin’s lymphoma. The Bulletin of Contemporary Clinical Medicine. 2022;15(6):56–61. EDN: WLWKLF doi: 10.20969/VSKM.2022.15(6).56-61
  14. Ofshenko N, Bercovich E, Mashiach T, et al. Reduction of the vertebral bone mineral density in patients with hodgkin lymphoma correlates with their age and the treatment regimen they received. Cancers (Basel). 2022;14(3):495. doi: 10.3390/cancers14030495
  15. Himpe J, Lammerant S, Van den Bergh L, et al. The impact of systemic oncological treatments on the fertility of adolescents and young adults-a systematic review. Life (Basel). 2023;13(5):1209. doi: 10.3390/life13051209
  16. Dvorakova J, Wiesnerova L, Chocholata P, et al. Human cells with osteogenic potential in bone tissue research. Biomed Eng Online. 2023;22(1):33. doi: 10.1186/s12938-023-01096-w
  17. Golds G, Houdek D, Arnason T. Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int J Endocrinol. 2017;2017:4602129. doi: 10.1155/2017/4602129
  18. Diab DL, Watts NB. Updates on osteoporosis in men. Endocrinol Metab Clin North Am. 2021;50(2):239–249. doi: 10.1016/j.ecl.2021.03.001.
  19. Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol. 2020;16(8):437–447. doi: 10.1038/s41574-020-0341-0
  20. Amin MSA, Brunckhorst O, Scott C, et al. ABVD and BEACOPP regimens’ effects on fertility in young males with Hodgkin lymphoma. Clin Transl Oncol. 2021;23(6):1067–1077. doi: 10.1007/s12094-020-02483-8

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Osteopenia/osteoporosis incidence according to the results of bone mineral density in men with Hodgkin’s lymphoma (%); * statistically significant differences at p <0.05

下载 (122KB)
索引源数据
3. Fig. 2. Osteopenia/osteoporosis incidence according to the results of the Z- and T-tests in men with Hodgkin’s lymphoma; * all differences are significant at p <0.05

下载 (192KB)
索引源数据

版权所有 © Eco-Vector, 2024

许可 URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г.